Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from scPharmaceuticals ( (SCPH) ).
On August 24, 2025, scPharmaceuticals entered into a merger agreement with MannKind Corporation, which will acquire all outstanding shares of scPharmaceuticals through a tender offer. The acquisition, valued at up to $360 million, aims to diversify and accelerate MannKind’s revenue growth, particularly with FUROSCIX, and strengthen its position in the cardiometabolic and lung disease sectors. The merger is expected to close in the fourth quarter of 2025, subject to regulatory approvals and customary conditions. This strategic move is anticipated to enhance MannKind’s market reach and integrate scPharmaceuticals’ commercial capabilities into its existing infrastructure.
The most recent analyst rating on (SCPH) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on scPharmaceuticals stock, see the SCPH Stock Forecast page.
Spark’s Take on SCPH Stock
According to Spark, TipRanks’ AI Analyst, SCPH is a Neutral.
scPharmaceuticals’ overall stock score is primarily influenced by its financial instability, marked by high debt levels and negative cash flows. Despite strong revenue growth and strategic advancements highlighted in the earnings call, the company’s valuation challenges and mixed technical indicators contribute to a lower score. The focus on improving financial health and operational efficiency remains crucial for future stability.
To see Spark’s full report on SCPH stock, click here.
More about scPharmaceuticals
scPharmaceuticals operates in the pharmaceutical industry, focusing on the development and commercialization of innovative treatments for conditions such as chronic heart failure and chronic kidney disease. Their primary product, FUROSCIX, is an FDA-approved on-body infuser delivering furosemide, addressing significant unmet needs in the U.S. market, which is estimated to have a total addressable market opportunity of over $10 billion.
Average Trading Volume: 318,245
Technical Sentiment Signal: Buy
Current Market Cap: $258.5M
Learn more about SCPH stock on TipRanks’ Stock Analysis page.